Literature DB >> 26458969

Retrospective study for risk factors for febrile UTI in spinal cord injury patients with routine concomitant intermittent catheterization in outpatient settings.

S Mukai1, K Shigemura2,3, M Nomi1, A Sengoku1, F Yamamichi2, M Fujisawa2, S Arakawa2,3.   

Abstract

STUDY
DESIGN: Retrospective study.
OBJECTIVES: The objective of this study was to investigate the clinical risk factors for febrile urinary tract infection (UTI) in spinal cord injury-associated neurogenic bladder (NB) patients who perform routine clean intermittent catheterization (CIC).
SETTING: Rehabilitation Hospital, Kobe, Japan.
METHODS: Over a 3-year period, we retrospectively assessed the clinical risk factors for febrile UTI in 259 spinal cord injury patients diagnosed as NB and performing routine CIC with regard to the factors such as gender, the presence of pyuria and bacteriuria, and the categories of the American Spinal Injury Association (ASIA) impairment scale.
RESULTS: A total of 67 patients had febrile UTI in the follow-up period, with 57 cases of pyelonephritis, 11 cases of epididymitis and 2 cases of prostatitis, including the patients with plural infectious diseases. The causative bacteria were ranked as follows: Escherichia coli (74 cases), Pseudomonas aeruginosa (17 cases), Enterococcus faecalis (14 cases) and Klebsiella pneumoniae (12 cases). Antibiotic-resistant E. coli were seen, with 10.5% instances of extended-spectrum β-lactamase (ESBL) production and 23.8% of fluoroquinolone resistance. Multivariate analyses of clinical risk factors for febrile UTI showed that gender (male, P=0.0431), and ASIA impairment scale C or more severe (P=0.0266) were significantly associated with febrile UTI occurrence in NB patients with routine CIC.
CONCLUSION: Our data demonstrated gender (male) and ASIA impairment scale C or more severe were significantly associated with febrile UTI occurrence in NB patients using routine CIC. Further prospective studies are necessary to define the full spectrum of possible risk factors for febrile UTI in these patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26458969     DOI: 10.1038/sc.2015.170

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  18 in total

1.  Validity, accuracy, and predictive value of urinary tract infection signs and symptoms in individuals with spinal cord injury on intermittent catheterization.

Authors:  Luiz M Massa; Jeanne M Hoffman; Diana D Cardenas
Journal:  J Spinal Cord Med       Date:  2009       Impact factor: 1.985

2.  Emergence of extended-spectrum β-lactamase-producing Escherichia coli in catheter-associated urinary tract infection in neurogenic bladder patients.

Authors:  Kei Takaba; Katsumi Shigemura; Kayo Osawa; Masashi Nomi; Masato Fujisawa; Soichi Arakawa
Journal:  Am J Infect Control       Date:  2014-03       Impact factor: 2.918

3.  Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.

Authors:  K Everaert; C Oostra; J Delanghe; J Vande Walle; M Van Laere; W Oosterlinck
Journal:  Spinal Cord       Date:  1998-01       Impact factor: 2.772

4.  Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases.

Authors:  C Peña; M Pujol; C Ardanuy; A Ricart; R Pallares; J Liñares; J Ariza; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

5.  Can neurologic examination predict type of detrusor sphincter-dyssynergia in patients with spinal cord injury?

Authors:  Brigitte Schurch; Daniel M Schmid; Gilles Karsenty; Andre Reitz
Journal:  Urology       Date:  2005-02       Impact factor: 2.649

6.  Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection.

Authors:  John M Quale; David Landman; Patricia A Bradford; Melissa Visalli; Jayshree Ravishankar; Carlos Flores; David Mayorga; Kalyani Vangala; Adedeyo Adedeji
Journal:  Clin Infect Dis       Date:  2002-09-10       Impact factor: 9.079

7.  Pyrexia in hospitalised spinal cord injury patients.

Authors:  P S Beraldo; E G Neves; C M Alves; P Khan; A C Cirilo; M R Alencar
Journal:  Paraplegia       Date:  1993-03

8.  Reused silicone catheter for clean intermittent catheterization (CIC): is it safe for spinal cord-injured (SCI) men?

Authors:  A Kovindha; W Na Chiang Mai; H Madersbacher
Journal:  Spinal Cord       Date:  2004-11       Impact factor: 2.772

9.  Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella.

Authors:  J J Rahal; C Urban; D Horn; K Freeman; S Segal-Maurer; J Maurer; N Mariano; S Marks; J M Burns; D Dominick; M Lim
Journal:  JAMA       Date:  1998-10-14       Impact factor: 56.272

10.  Risk factors for upper tract deterioration in chronic spinal cord injury patients.

Authors:  R G Gerridzen; A M Thijssen; E Dehoux
Journal:  J Urol       Date:  1992-02       Impact factor: 7.450

View more
  3 in total

1.  Risk factors for febrile genito-urinary infection in the catheterized patients by with spinal cord injury-associated chronic neurogenic lower urinary tract dysfunction evaluated by urodynamic study and cystography: a retrospective study.

Authors:  Katsumi Shigemura; Koichi Kitagawa; Masashi Nomi; Akihiro Yanagiuchi; Atsushi Sengoku; Masato Fujisawa
Journal:  World J Urol       Date:  2019-04-04       Impact factor: 4.226

Review 2.  The microbiome and host mucosal interactions in urinary tract diseases.

Authors:  Bernadette Jones-Freeman; Michelle Chonwerawong; Vanessa R Marcelino; Aniruddh V Deshpande; Samuel C Forster; Malcolm R Starkey
Journal:  Mucosal Immunol       Date:  2021-02-04       Impact factor: 7.313

3.  Results after implementation of a protocol on the incidence of urinary tract infection in an intensive care unit.

Authors:  Anna Letícia Miranda; Ana Lúcia Lyrio de Oliveira; Daiana Terra Nacer; Cynthia Adalgisa Mesojedovas Aguiar
Journal:  Rev Lat Am Enfermagem       Date:  2016-09-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.